Eikon Therapeutics, Inc. Common Stock (EIKN) vs Strata Critical Medical, Inc. (SRTA)
A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and Strata Critical Medical, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EIKN
Eikon Therapeutics, Inc. Common Stock
$7.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SRTA
Strata Critical Medical, Inc.
$4.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EIKN vs SRTA
growth of $100 · dividends reinvested · last 1yEIKN -49.7% (-49.7%/yr)SRTA +9.3% (+9.3%/yr)SRTA compounded faster over this window
EIKN SRTA
EIKN vs SRTA: by the numbers
- •SRTA is the larger company ($411M vs $407M market cap).
- •SRTA is profitable (15.71% net margin) while EIKN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | EIKN | SRTA |
|---|---|---|
| P/E ratio | N/A | 9.54 |
| P/S ratio | N/A | 1.61 |
| P/B ratio | 0.87 | 1.47 |
Profitability
| Metric | EIKN | SRTA |
|---|---|---|
| Gross margin | 0.00% | 20.56% |
| Operating margin | 0.00% | -7.97% |
| Net margin | 0.00% | 15.71% |
| ROE | -69.06% | 14.40% |
| ROIC | -46.16% | -7.11% |
Growth (annualized)
| Metric | EIKN | SRTA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 46.05% |
| Total return CAGR (5Y) | N/A | -13.77% |
Frequently asked
- Is EIKN or SRTA more profitable?
- SRTA runs the higher net margin — EIKN at 0.00% versus SRTA at 15.71%.
Go deeper
Dig into the metrics
Strata Critical Medical P/E ratioEikon Therapeutics, Inc. Common Stock ROEStrata Critical Medical ROEEikon Therapeutics, Inc. Common Stock operating marginStrata Critical Medical operating marginEikon Therapeutics, Inc. Common Stock revenue growthStrata Critical Medical revenue growthEikon Therapeutics, Inc. Common Stock free cash flowStrata Critical Medical free cash flow
Eikon Therapeutics, Inc. Common Stock & Strata Critical Medical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.